jm6b01839_si_002.csv (4.19 kB)
Download fileStructure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain
dataset
posted on 04.04.2017, 00:00 authored by R. Aldrin Denny, Andrew C. Flick, Jotham Coe, Jonathan Langille, Arindrajit Basak, Shenping Liu, Ingrid Stock, Parag Sahasrabudhe, Paul Bonin, Duncan A. Hay, Paul E. Brennan, Mathew Pletcher, Lyn H. Jones, Eugene L. Piatnitski CheklerChemical
probes are required for preclinical target validation
to interrogate novel biological targets and pathways. Selective inhibitors
of the CREB binding protein (CREBBP)/EP300 bromodomains are required
to facilitate the elucidation of biology associated with these important
epigenetic targets. Medicinal chemistry optimization that paid particular
attention to physiochemical properties delivered chemical probes with
desirable potency, selectivity, and permeability attributes. An important
feature of the optimization process was the successful application
of rational structure-based drug design to address bromodomain selectivity
issues (particularly against the structurally related BRD4 protein).
History
Usage metrics
Read the peer-reviewed publication
Categories
Keywords
BRD 4 proteinstructure-based drug designaddress bromodomain selectivity issuespermeability attributesoptimization processStructure-Based DesignCREB binding proteinSelective inhibitorsMedicinal chemistry optimizationtarget validationchemical probesSelective InhibitorsCREB Binding Protein Bromodomain Chemical probesCREBBP